LYRA — Lyra Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $1.15m
- -$14.74m
- $0.40m
Annual cashflow statement for Lyra Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -43.5 | -55.3 | -62.7 | -93.4 | -28.9 |
| Depreciation | |||||
| Non-Cash Items | 2.77 | 6.27 | 3.98 | 29.3 | 2.33 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 13.9 | 4.55 | -4.88 | -6.35 | -2.73 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -25.8 | -43.4 | -63.3 | -70 | -28.9 |
| Capital Expenditures | -3.38 | -0.164 | -1.05 | -2.34 | -0.116 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -64.8 | -11.5 | 82.6 | 0.018 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -3.38 | -65 | -12.6 | 80.3 | -0.098 |
| Financing Cash Flow Items | -0.245 | -4.25 | -3.65 | -0.29 | -0.726 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 0.359 | 96.3 | 65.7 | 8.53 | 4.27 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -28.8 | -12.1 | -10.2 | 18.8 | -24.7 |